Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

导出原文传递

翻译打印收藏纠错

第一作者： Tom,Martin

第一单位： School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

作者： Tom,Martin ^[1] ; Saad Z,Usmani ^[2] ; Jordan M,Schecter ^[3] ; Tito,Roccia ^[3] ; Carolyn C,Jackson ^[3] ; William,Deraedt ^[4] ; Tzu-Min,Yeh ^[3] ; Arnob,Banerjee ^[5] ; Lida,Pacaud ^[6] ; Ashraf,Garrett ^[6] ; Meaghan,Bartlett ^[7] ; Anja,Haltner ^[8] ; Suzy,Van Sanden ^[4] ; Joris,Diels ^[4] ; Satish,Valluri ^[3] ; Imtiaz A,Samjoo ^[7]

作者单位： School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. ^[1] Department of Medicine, Levine Cancer Institute-Atrium Health, Charlotte, NC, USA. ^[2] Janssen Global Services, Raritan, NJ, USA. ^[3] Janssen R&D, Beerse, Belgium. ^[4] Janssen R&D, Spring House, PA, USA. ^[5] Legend Biotech USA, Inc, Piscataway, NJ, USA. ^[6] EVERSANA, Burlington, Ontario, Canada. ^[7] EVERSANA, Chicago, IL, USA. ^[8]

关键词 CARTITUDE-1 KarMMa ciltacabtagene autoleucel idecabtagene vicleucel indirect treatment comparison relapsed or refractory multiple myeloma

主题词人类(Humans);多发性骨髓瘤(Multiple Myeloma);抗肿瘤药(Antineoplastic Agents)

DOI 10.1080/03007995.2022.2139052

PMID 36271807

发布时间 2023-02-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交